POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Clinical trials for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER explained in plain language.
Never miss a new study
Get alerted when new POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER trials appear
Sign up with your email to follow new studies for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for transplant patients: drug duo targets rare cancer
Disease control Not yet recruitingThis study tests two drugs, loncastuximab tesirine and rituximab, as a first treatment for a rare blood cancer called post-transplant lymphoproliferative disorder (PTLD) that can occur after an organ transplant. The first part finds the safest dose, and the second part checks how…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1, PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 11, 2026 12:11 UTC
-
Could a cancer drug stop a deadly complication in transplant patients?
Prevention Not yet recruitingThis study tests whether the drug rituximab can safely clear Epstein-Barr virus (EBV) from the blood of people who have received a solid organ transplant. High levels of EBV can lead to a serious cancer called post-transplant lymphoproliferative disorder (PTLD). The trial will en…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1 • Sponsor: Jennifer Amengual • Aim: Prevention
Last updated Jun 02, 2026 11:58 UTC